产品名称：宾达利
产品别名：**Bindarit**

生物活性：

Description	Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity[1].
IC_{50} & Target	MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8[1].
In Vitro	Bindarit (10-300 μM; 48 hours) at 100 μM and 300 μM significantly inhibits platelet derived growth factor-BB (PDGF-BB)-induced rat VSMCs proliferation by 27% and 42%, respectively[1].

Cell Viability Assay[1]

Cell Line:	VSMC cells
Concentration:	10 μM, 30 μM, 100 μM, 300 μM
Incubation Time:	48 hours
Result:	Inhibited PDGF-BB-induced rat VSMCs proliferation.

In Vivo	Bindarit (50 mg/kg; oral administration; every day; for 4 months, 6 months, 8 months; NZB/W F1 female mice) delays the onset of proteinuria and significantly protects from renal function impairment. Bindarit completely prevents monocyte chemoattractant protein (MCP-1) up-regulation[2].
Animal Model:	NZB/W F1 female mice (two months of age) [2]
Dosage:	50 mg/kg
Administration:	Oral administration; every day; for 4 months, 6 months, 8 months
Result:	Delayed the onset of proteinuria and significantly protected from renal function impairment.

Solvent&Solubility

In Vitro:

DMSO : ≥ 46 mg/mL (141.81 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0829 mL	15.4145 mL	30.8290 mL
	5 mM	0.6166 mL	3.0829 mL	6.1658 mL
	10 mM	0.3083 mL	1.5414 mL	3.0829 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 **In Vitro** 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline

Solubility: ≥ 2.67 mg/mL (8.23 mM); Clear solution

	此方案可获得 ≥ 2.67 mg/mL (8.23 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 26.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。 2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.67 mg/mL (8.23 mM); Clear solution 此方案可获得 ≥ 2.67 mg/mL (8.23 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 26.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: 2.67 mg/mL (8.23 mM); Clear solution; Need warming 此方案可获得 2.67 mg/mL (8.23 mM)的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 26.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。
References	[1]. Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93. [2]. Zoja C, Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998 Mar;53(3):726-34.